Contineum Therapeutics (CTNM) EBITDA (2023 - 2026)

Contineum Therapeutics' EBITDA history runs 4 years deep, the most recent figure standing at -$15.0 million for Q1 2026.

• In Q1 2026, EBITDA rose 5.8% year-over-year to -$15.0 million; the TTM figure through Mar 2026 stood at -$58.9 million (down 18.68% YoY), while the FY2025 annual figure was -$59.8 million, down 41.36% from the prior year.
• EBITDA was -$15.0 million for Q1 2026 at Contineum Therapeutics, up from -$15.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $41.5 million in Q2 2023 to a low of -$16.1 million in Q2 2025.
• Historically, EBITDA has averaged -$7.2 million across 4 years, with a median of -$9.6 million in 2024.
• The sharpest annual moves came in 2024 and 2026: EBITDA tumbled 121.87% in 2024, then advanced 5.8% in 2026.
• A 4-year view of EBITDA shows it stood at -$7.6 million in 2023, then sank by 98.82% to -$15.1 million in 2024, then retreated by 0.7% to -$15.2 million in 2025, then rose by 1.27% to -$15.0 million in 2026.
• The last three EBITDA figures came in at -$15.0 million (Q1 2026), -$15.2 million (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.